MARKET WIRETradingView • 21h ago
Eikon Therapeutics, Inc. Estimates – NASDAQ:EIKNTradingView report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
Why EIKN Stock surged +6.97% Today — RQD Quant Desk Flash
$5.68 +6.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.74
Eikon Therapeutics Inc. (EIKN) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $287.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on EIKN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is EIKN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Eikon Therapeutics Inc. (NASDAQ: EIKN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $5.68 (+6.97% 1D, market cap $287.6M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does EIKN compare to SCTX and SABS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EIKN carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SCTX (Scribe Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $291.9M) and SABS (SAB Biotherapeutics Inc.) posts a D- grade (38/100 RQD, P/E 22.1x, ROIC -27.4%, cap $304.8M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for EIKN?
▼
Per EIKN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861123), Eikon Therapeutics Inc. generated $249.8M in revenue, $0 in net income, and $0 in free cash flow against $594.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.74 (+1.06%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 3.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EIKN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY EIKN SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 3.2% FCF Margin ($8.1M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$6.72+21.7% Next Q
51
Q2 (-2Q)Grade D$8.18-32.2% Next Q
48
Q3 (-1Q)Grade D$5.55+2.3% Next Q
46
CurrentGrade D-$5.68-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a EIKN Turnaround Squeeze
While EIKN currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.35) and Max Pain ($5.96) forces dealer call-delta covering toward $18.27.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EIKN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EIKN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EIKN Stock surged +6.97% Today — RQD Quant Desk Flash
Eikon Therapeutics Inc. (EIKN) surged +6.97% to $5.68, trading at 5% of its 52-week range ($5.01 – $17.4). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($5.01 – $17.4) with RSI-14 at 28.6 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.68 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: EIKN Exhibits 4.27x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live EIKN Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology CongressYahoo Finance report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A prostate cancer drug candidate targets variants tied to treatment resistance. Eikon filed it with the FDA.Stock Titan report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Eikon Therapeutics (NASDAQ:EIKN) Stock Rated "Buy" in New Coverage at HC WainwrightMarketBeat report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
Is Eikon Therapeutics (NASDAQ:EIKN) In A Good Position To Invest In Growth?Simply Wall St report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology CongressYahoo Finance report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
HC Wainwright & Co. initiates coverage of Eikon Therapeutics with Buy rating, $23 price targetTradingView report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Eikon Therapeutics, Inc. $EIKN Shares Newly Bought by Regents of The University of CaliforniaMarketBeat report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 8d ago
Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient SettingEIK1001 Clinical Update:Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with
MARKET WIREBenzinga • 11d ago
Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated ProfileEikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EIKN)
- ✓Walkthrough of EIKN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EIKN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.69%🛡️ HOLDING TREND SUPPORT
2026-11-03O $5.35H $5.68L $5.31C $5.68VOL 553.1K
RES: $15.32SUP: $4.90SMA50: $8.35SMA200: $10.38
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EIKN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on EIKN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EIKN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EIKN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EIKN)
Health Care Rank #410 of 1016
⚔️ SCTX vs EIKN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EIKN vs. SCTX, SABS, AGEN, IPSC)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Eikon Therapeutics Inc. (EIKN) ranks #410 by composite RQD confidence (43/100, grade D-) and #522 by equity capitalization ($287.6M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. EIKN currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EIKN
ACTIVE
Eikon Therapeutics Inc. | D- | 43/100 | — | — | — | +6.97% | $287.6M | Benchmark Subject |
| SCTX Scribe Therapeutics Inc. | D- | 43/100 | — | — | — | +0.78% | $291.9M | /sctx-vs-eikn → |
| SABS SAB Biotherapeutics Inc. | D- | 38/100 | 22.1x | — | -27.4% | -1.49% | $304.8M | /sabs-vs-eikn → |
| AGEN Agenus Inc. | E | 29/100 | — | 96.0% | -35.0% | -4.53% | $308.9M | /agen-vs-eikn → |
| IPSC Century Therapeutics Inc. | E | 18/100 | — | — | -14.1% | +0.68% | $266.2M | /ipsc-vs-eikn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001861123In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eikon Therapeutics Inc. (EIKN) reported GAAP revenue of $249.8M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, EIKN closed FY2025 with $594.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $249.8M | $0 | — | — | $594.7M | — |
3. EIKN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EIKN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Eikon Therapeutics Inc. (NASDAQ: EIKN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $5.68 (+6.97% 1D, market cap $287.6M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
How does EIKN compare to SCTX and SABS in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EIKN carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SCTX (Scribe Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $291.9M) and SABS (SAB Biotherapeutics Inc.) posts a D- grade (38/100 RQD, P/E 22.1x, ROIC -27.4%, cap $304.8M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EIKN?
Per EIKN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861123), Eikon Therapeutics Inc. generated $249.8M in revenue, $0 in net income, and $0 in free cash flow against $594.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EIKN trading relative to its 50-day, 200-day, and 52-week technical levels?
EIKN last traded at $5.68 (+6.97% on volume of 410,051 shares), positioning the stock -31.98% below its 50-day simple moving average ($8.35) and -45.28% below its 200-day simple moving average ($10.38). Across its 52-week range of $5.01 to $17.40, EIKN sits at the 5.4% percentile with a 14-day RSI of 28.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.97 to $6.39).
ROARABLE RATING BRIEF • RQD 43/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
EIKN — Eikon Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:52Z
1. Roarable Rating Brief: What This Means to a Prospective Investor
EIKN scores 42 out of 100 and carries a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:
- Fundamental Cash Engine: 10 / 20 (ROIC 0%; FCF yield 0%). The cash-generation pillar is weak because the source data shows no reported return on invested capital and no free-cash-flow yield.
- Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). This is the lowest pillar score, indicating weak institutional support in the rating's view. The holders section contains no 13F detail to explain the score.
- Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). The score is below midpoint; the source data contains no insider transaction detail to explain it.
- Macro Regime Fit: 7 / 20 (beta 1.0; sector sensitivity). The beta of 1.0 is market-equivalent, and the rating assigns limited credit for regime fit.
- Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, with moderate balance-sheet metrics.
For a prospective investor, the practical implication is that the rating's weakest inputs are cash generation and institutional flow, while the balance sheet is the relatively stronger leg. The source data reports no revenue, no operating income, and no net income for FY 2025, so the cash-engine score rests on absent earnings rather than on measured losses. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are unavailable. The rating does not state its methodology beyond the pillar labels, so the weighting of each input is not verifiable from the source data.
2. Business Model, Unit Margins & SEC Financial Trajectory
Eikon Therapeutics Inc. Is listed on NASDAQ and classified under the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..3B.
FY 2025 reports — in revenue, operating income, and net income, with cash of $104.9M. Gross, operating, and net margins are each reported as 0%, and ROIC is 0%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5, which together describe a balance sheet with moderate forensic strength despite the absence of reported earnings. Debt is listed as N/A in the SEC financials, so the 0.5 Debt/Equity figure cannot be reconciled to a reported debt amount within this dataset.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: The balance sheet pillar is the rating's strongest input at 13/20, supported by a 2.5 Altman Z-Score and $104.9M in reported cash. With Fundamental Cash Engine at 10/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $5.01 – $17.40 52-week range.
- 🐻 Primary Bear Case: The Butterfly liquidity signal scores a BEARISH 18/100 MACRO TAILWIND with a 4.27x net-liquidity beta, while the company reports $0.0M in revenue and 0% ROIC. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies are therefore — The graph's sector is Health Care and its industry is Biotechnology: Biological Products (No Diagnostic Substances), but no sector-correlation data beyond the liquidity signal is provided. The only second-order channel described in the source is the liquidity linkage: the signal attributes elevated sensitivity to net-liquidity swings, so a tightening or widening move in the cited liquidity measures would be a second-order ripple for this name. Investors should watch the liquidity inputs the signal cites, since the source data identifies them as the primary transmission mechanism.
- Key Question #1: What is the cash runway implied by $104.9M in cash against an absent debt figure and zero operating income?
- Key Question #2: What is the status and timeline of the FDA filing and clinical programs referenced in recent news, and what regulatory or trial milestones are scheduled?
- Key Question #3: What explains the 0.5 Debt/Equity ratio when the SEC financials report debt as N/A?
EIKN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Eikon Therapeutics Inc. (EIKN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 21h ago
Eikon Therapeutics, Inc. Estimates – NASDAQ:EIKN TradingView report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress Yahoo Finance report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A prostate cancer drug candidate targets variants tied to treatment resistance. Eikon filed it with the FDA. Stock Titan report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Eikon Therapeutics (NASDAQ:EIKN) Stock Rated "Buy" in New Coverage at HC Wainwright MarketBeat report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
Is Eikon Therapeutics (NASDAQ:EIKN) In A Good Position To Invest In Growth? Simply Wall St report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress Yahoo Finance report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
HC Wainwright & Co. initiates coverage of Eikon Therapeutics with Buy rating, $23 price target TradingView report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Eikon Therapeutics, Inc. $EIKN Shares Newly Bought by Regents of The University of California MarketBeat report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
EIKN Bull vs. Bear Conversation Board — What's Your Call at $5.68?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EIKN 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 Options Flow Specialist 🐂 BULLISH
🎯 Target: $6.90 (+29.9%)
📌 Pinned Debate The balance sheet pillar is the rating's strongest input at 13/20, supported by a 2.5 Altman Z-Score and $104.9M in reported cash.
Here is why I am bullish on EIKN here at $5.31: The balance sheet pillar is the rating's strongest input at 13/20, supported by a 2.5 Altman Z-Score and $104.9M in reported cash.. Compare EIKN's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $5.04 are getting bought.
SectorRotator 🐂 BULL
@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
RI RiskArb_Desk Hedged Event Driven 🐻 BEARISH
🎯 Target: $4.35 (-18.1%)
Spot @ $5.31 The Butterfly liquidity signal scores a BEARISH 18/100 MACRO TAILWIND with a 4.27x net-liquidity beta, while the company reports $0.0M
The Butterfly liquidity signal scores a BEARISH 18/100 MACRO TAILWIND with a 4.27x net-liquidity beta, while the company reports $0.0M in revenue and 0% ROIC.. Look at the math on EIKN: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $4.67 before getting long.